News

Connect with Inverna Therapeutics at BIO-Europe Spring 2026 and LSX World Congress Europe 2026

Connect with Inverna Therapeutics at BIO-Europe Spring 2026 and LSX World Congress Europe 2026

March 6, 2026

Inverna Therapeutics is pleased to announce its participation in the Life Science Spring Innovation Week 2026, featuring BIO-Europe Spring 2026, held March 23 – 25, 2026, and the directly following LSX World Congress Europe 2026, March 25 – 26, 2026.

Read more

Inverna Therapeutics to Showcase Breakthrough Pseudo-Exon Activation Platform at RNA Leaders Europe Congress

Inverna Therapeutics to Showcase Breakthrough Pseudo-Exon Activation Platform at RNA Leaders Europe Congress

March 6, 2026

Inverna Therapeutics is pleased to announce that Chief Executive Officer, Poul Sørensen, has been invited to present at the RNA Leaders Europe 2026 Congress, taking place from March 17 to 19, 2026, at the Austria Center in Vienna.

Read more

Inverna Therapeutics will be presenting at BioCapital 2026

Inverna Therapeutics will be presenting at BioCapital 2026

February 23, 2026

Inverna Therapeutics is pleased to announce that CEO Poul Sørensen will be presenting at the upcoming BioCapital 2026 conference organized by EQT Life Sciences.

Read more

Inverna Therapeutics announces the formation of its Scientific Advisory Board consisting of world-renowned leaders in RNA therapeutics and neurodegenerative research

Inverna Therapeutics announces the formation of its Scientific Advisory Board consisting of world-renowned leaders in RNA therapeutics and neurodegenerative research

October 29, 2025

The grant will support development of Inverna’s novel RNA therapy targeting LRRK2 to advance precision medicine approaches for Parkinson’s disease.

Read more

Inverna Therapeutics awarded grant from the Michael J. Fox Foundation for Parkinson’s research

Inverna Therapeutics awarded grant from the Michael J. Fox Foundation for Parkinson’s research

October 9, 2025

The grant will support development of Inverna’s novel RNA therapy targeting LRRK2 to advance precision medicine approaches for Parkinson’s disease.

Read more

Inverna Therapeutics will participate in BIO-Europe 2025

Inverna Therapeutics will participate in BIO-Europe 2025

October 5, 2025

We are excited to participate in BIO-Europe 2025 and are looking forward to connect!

Read more

Inverna Therapeutics to showcase its groundbreaking RNA therapeutics platform at Nordic Life Science Days 2025

Inverna Therapeutics to showcase its groundbreaking RNA therapeutics platform at Nordic Life Science Days 2025

September 22, 2025

We are excited to participate in the NLSDays and honored to be selected as a finalist for the Nordic Star Pitch Competition.

Read more

Next-generation RNA company Inverna Therapeutics launched by Argobio and University of Southern Denmark

Next-generation RNA company Inverna Therapeutics launched by Argobio and University of Southern Denmark

January 7, 2025

The grant will support development of Inverna’s novel RNA therapy targeting LRRK2 to advance precision medicine approaches for Parkinson’s disease.

Read more